Hannah Clarke

"The sad thing is that with something like OAB, we already have so many barriers to getting patients in to initiate care in the first place," says A. Lenore Ackerman, MD, PhD.

“There is a lack of information regarding the prevalence and implications of [prostate cancer] in transgender women, and this highlights the crucial need for further research into prevention, detection, and treatment," says Hayley Premo.

“Our data indicate that usage of a PCNL equipment whiteboard led to significant improvements in team perception of inter-disciplinary communication and case item selection accuracy," says Jenny N. Guo, MD.

"The evidence is starting to show us that although efficacy in terms of managing OAB symptoms may be equal or similar across studies for these 2 classes of medications, safety and tolerability are very different," says A. Lenore Ackerman, MD, PhD.

In this installment, Jonathan Clavell, MD, FACS, highlights Clavell Urology, his private practice within Robert J Cornell MD, PA, in Houston, Texas.

"Our preliminary clinical trial found that TAR-200 was generally safe, well tolerated, and had beneficial effects on bladder cancer outcomes in a group of patients with limited treatment options," said Mark Tyson, MD, MPH.

Investigators found that the total out-of-pocket costs associated with oral therapies for prostate cancer were approximately 18 times higher compared with ADT.

"[This] could be a paradigm shift in prostate cancer,” says Eugene Shenderov, MD, PhD.

In combination, the number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and the mutations of PBRM1 can serve as biomarkers of response to immunotherapy in patients with kidney cancer.

"When we put this course together, we didn't want it to be a course about working more; it was really about working more efficiently, so that you can gain more time outside of work," says Angela B. Smith, MD, MS.

At 5-year follow-up, overall survival among patients with kidney cancer who had quit smoking was 85% compared with 61% for those that continued to smoke.

"We are caring for a variety of patients who do not look like the physicians who are providing care to them," says Akanksha Mehta, MD, MS.

"We are confident that surgery for [testicular seminoma] will be included into treatment guidelines in the near future,” says Sia Daneshmand, MD.

“These disparities are concerning as the generalizability of clinical trial results relies on the assumption that the population of patients included in a clinical trial represents the overall population of patients with the disease," says Brian M. Shinder, MD.

"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.

Patients received standard-of-care testosterone suppression with either oral enzalutamide or standard non-steroidal antiandrogen therapy.

"The improvement in technologies could potentially assist radiation oncologists in making timely decisions,” said Himanshu Arora, PhD.

"Some of these patients newly referred don't have any other proven therapies remaining...This is the only one on the shelf that has a proven benefit. Unfortunately, we can't offer them that at this stage," says Praful Ravi, MD, BChir, MRCP.

No CxM-negative patients had findings of a recurrent tumor on a follow-up cystoscopy.

In 2021, small urology programs had 28.1% spots filled by applicants at their home program, compared with 16.2% between 2016 and 2020.

"With ARASTEP, we are optimistic about the potential to help patients at this earlier stage of [prostate cancer]," says Tara Frenkl, MD.

"While CBD oil appears safe, it does not seem to reduce pain or discomfort during the typically brief recovery period after this common procedure,” says Karen Stern, MD.

"The results of this study demonstrate that peroneal eTNM using the URIS neuromodulation system is safe, well tolerated, and effective, with over 85% of patients experiencing clinically significant improvement in most bothersome OAB symptoms," says Jan Krhut, PhD.

Urologic oncology represented the largest subspecialty on Twitter with 225 active members and the highest followers, likes, and tweets per day.

The highest cumulative 120-day rates of ED visits and HA were observed in patients who underwent percutaneous nephrolithotomy procedures.

"UH is working on starting clinics throughout rural Northeast Ohio, and we're meeting to develop a FPMRS program, both virtual and in-person, so patients can have access to this point of care," says David Sheyn, MD.

Findings suggest many patients with localized disease can delay surgery or radiation without increasing their mortality risk.

“The more we can use AI to streamline all the less attractive aspects of our job, the better,” says David Canes, MD.

"The government is spending more in Medicare, we are getting more people with prostate cancer, more deaths with prostate cancer, [and] more metastasis with prostate cancer. While it is so simple: today, PSA is still there," says Navin Shah, MD, MS, FACS, FICS, FACIP.

The investigators used data from the National Inpatient Sample database to identify 5280 patients with non-metastatic bladder cancer who underwent RC from 2016 to 2019.